Human treg cells are characterized by low/negative CD6 expression

Cytometry Part A

Volumn 85, Issue 10, 2014, Pages 901-908

  Garcia Santana, Carlos A ^a   Tung, James W ^a   Gulnik, Sergei ^a  

^a BECKMAN COULTER INC   (United States)

Author keywords

CD6; FOXP3; Human T cells; Natural regulatory T cells; NTreg; Treg; Treg associated markers

Indexed keywords

CD6 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN;

BIOSYNTHESIS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; MONONUCLEAR CELL; PROCEDURES; REGULATORY T LYMPHOCYTE;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; T-LYMPHOCYTES, REGULATORY;

EID: 84927691193     PISSN: 15524922     EISSN: 15524930     Source Type: Journal    
DOI: 10.1002/cyto.a.22513     Document Type: Article

References (43)

1. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
2. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009;30:636-645.
3. Piccirillo CA. Regulatory T cells in health and disease. Cytokine 2008;43:395-401.
4. Dinesh RK, Skaggs BJ, La Cava A, Hahn BH, Singh RP. CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev 2010;9:560-568.
5. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
6. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000;192:303-310.
7. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
8. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232.
9. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC. CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-323.
10. Solstad T, Bains SJ, Landskron J, Aandahl EM, Thiede B, Tasken K, Torgersen KM. CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells. Blood 2011;118:5141-5151.
11. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001;194:847-853.
12. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005;105:2877-2886.
13. Tosello V, Odunsi K, Souleimanian NE, Lele S, Shrikant P, Old LJ, Valmori D, Ayyoub M. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clin Immunol 2008;126:291-302.
14. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 2006;176:2808-2816.
15. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013;190:2001-2008.
16. Wang R, Kozhaya L, Mercer F, Khaitan A, Fujii H, Unutmaz D. Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells. Proc Natl Acad Sci U S A 2009;106:13439-13444.
17. Nagata S, Ise T, Pastan I. Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J Immunol 2009;182:7518-7526.
18. Crellin NK, Garcia RV, Levings MK. Flow cytometry-based methods for studying signaling in human CD4+CD25+FOXP3+ T regulatory cells. J Immunol Methods 2007;324:92-104.
19. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203:1701-1711.
20. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203:1693-1700.
21. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O, Falk K. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 2009;113:827-836.
22. Salgado FJ, Perez-Diaz A, Villanueva NM, Lamas O, Arias P, Nogueira M. CD26: A negative selection marker for human Treg cells. Cytometry Part A 2012;81A:843-855.
23. Reiter C. Cluster report: CD6. In: Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, editors. Leucocyte Typing IV: White Cell Differentiation Antigens. New York: Oxford University Press; 1989. p 339.
24. Gangemi RM, Swack JA, Gaviria DM, Romain PL. Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes. J Immunol 1989;143:2439-2447.
25. Kamoun M, Kadin ME, Martin PJ, Nettleton J, Hansen JA. A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. J Immunol 1981;127:987-991.
26. Mayer B, Funke I, Seed B, Riethmuller G, Weiss E. Expression of the CD6 T lymphocyte differentiation antigen in normal human brain. J Neuroimmunol 1990;29:193-202.
27. Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: In vitro analysis of CD6-CD166 interactions. Proteins 2000;40:420-428.
28. Osorio LM, Garcia CA, Jondal M, Chow SC. The anti-CD6 mAb, IOR-T1, defined a new epitope on the human CD6 molecule that induces greater responsiveness in T cell receptor/CD3-mediated T cell proliferation. Cell Immunol 1994;154:123-133.
29. Singer NG, Richardson BC, Powers D, Hooper F, Lialios F, Endres J, Bott CM, Fox DA. Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes. Immunology 1996;88:537-543.
30. Patel DD, Wee SF, Whichard LP, Bowen MA, Pesando JM, Aruffo A, Haynes BF. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med 1995;181:1563-1568.
31. Nair P, Melarkode R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010;162:116-130.
32. Oliveira MI, Goncalves CM, Pinto M, Fabre S, Santos AM, Lee SF, Castro MA, Nunes RJ, Barbosa RR, Parnes JR, et al. CD6 attenuates early and late signaling events, setting thresholds for T-cell activation. Eur J Immunol 2012;42:195-205.
33. Pinto M, Carmo AM. CD6 as a therapeutic target in autoimmune diseases: Successes and challenges. BioDrugs: Clin Immunother, Biopharma Gene Therapy 2013;27:191-202.
34. Rasmussen RA, Counts SL, Daley JF, Schlossman SF. Isolation and characterization of CD6-T cells from peripheral blood. J Immunol 1994;152:527-536.
35. Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol 2001;19:1152-1159.
36. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117:1061-1070.
37. Grant J, Bourcier K, Wallace S, Pan D, Conway A, Seyfert-Margolis V, Wallace PK. Validated protocol for FoxP3 reveals increased expression in type 1 diabetes patients. Cytometry B Clin Cytom 2009;76B:69-78.
38. Tario JD Jr, Humphrey K, Bantly AD, Muirhead KA, Moore JS, Wallace PK. Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes. J Visual Exp 2012;13:e4287.
39. Venken K, Thewissen M, Hellings N, Somers V, Hensen K, Rummens JL, Stinissen P. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J Immunol Methods 2007;322:1-11.
40. Klein S, Kretz CC, Krammer PH, Kuhn A. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol 2010;130:492-499.
41. Burton CT, Westrop SJ, Eccles-James I, Boasso A, Nelson MR, Bower M, Imami N. Altered phenotype of regulatory T cells associated with lack of human immunodeficiency virus (HIV)-1-specific suppressive function. Clin Exp Immunol 2011;166:191-200.
42. Ukena SN, Hopting M, Velaga S, Ivanyi P, Grosse J, Baron U, Ganser A, Franzke A. Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. Exp Hematol 2011;39:1152-1160.
43. Gimferrer I, Calvo M, Mittelbrunn M, Farnos M, Sarrias MR, Enrich C, Vives J, Sanchez-Madrid F, Lozano F. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 2004;173:2262-2270.